HomeCompareCFNCF vs ABBV

CFNCF vs ABBV: Dividend Comparison 2026

CFNCF yields 2.29% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $75.9K in total portfolio value
10 years
CFNCF
CFNCF
● Live price
2.29%
Share price
$356.88
Annual div
$8.16
5Y div CAGR
12.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.4K
Annual income
$936.68
Full CFNCF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — CFNCF vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCFNCFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CFNCF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CFNCF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CFNCF
Annual income on $10K today (after 15% tax)
$194.35/yr
After 10yr DRIP, annual income (after tax)
$796.18/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $20,259.83/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CFNCF + ABBV for your $10,000?

CFNCF: 50%ABBV: 50%
100% ABBV50/50100% CFNCF
Portfolio after 10yr
$64.4K
Annual income
$12,854.22/yr
Blended yield
19.97%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

CFNCF
No analyst data
Altman Z
6.4
Piotroski
6/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CFNCF buys
0
ABBV buys
7
PoliticianChamberTickerTypeAmountDate
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-18
Julia Letlow🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-08
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-11-13
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-31
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-30
Lisa McClain🏢 House$ABBV▲ Buy$1,001 - $15,0002025-10-30
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-08-14
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-11
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCFNCFABBV
Forward yield2.29%3.06%
Annual dividend / share$8.16$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR12.2%40.6%
Portfolio after 10y$26.4K$102.3K
Annual income after 10y$936.68$24,771.77
Total dividends collected$5.3K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CFNCF vs ABBV ($10,000, DRIP)

YearCFNCF PortfolioCFNCF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$10,957$256.54$11,550$430.00$593.00ABBV
2$12,018$294.74$13,472$627.96$1.5KABBV
3$13,199$339.02$15,906$926.08$2.7KABBV
4$14,513$390.40$19,071$1,382.55$4.6KABBV
5$15,979$450.14$23,302$2,095.81$7.3KABBV
6$17,617$519.70$29,150$3,237.93$11.5KABBV
7$19,451$600.83$37,536$5,121.41$18.1KABBV
8$21,508$695.62$50,079$8,338.38$28.6KABBV
9$23,820$806.57$69,753$14,065.80$45.9KABBV
10$26,425$936.68$102,337$24,771.77$75.9KABBV

CFNCF vs ABBV: Complete Analysis 2026

CFNCFStock

Compagnie Financière Tradition SA operates as an interdealer broker of financial and non-financial products worldwide. It provides capital market products, including basis swaps, credit and currency derivatives, inflation products, Latin American derivatives, non-deliverable swaps, overnight index swaps, short dates, and Turkish fixed income and money market, as well as interest rate derivatives, options, and swaps. The company also offers energy and commodity products, such as coal, electricity, environmental products, natural gas, oil, precious metals, property derivatives, pulp and paper, refined products, soft commodities, tradition energy, weather, LNG, petroleum and LPG, and renewable energy credits. In addition, it provides equities comprising cash and preferred equities, equity derivatives, ETFs, institutional cash equities, single-stock options, delta-one products, exotics, post-reorg equities, index variance and equity finance swaps, and dividend swaps; and fixed income products consisting of asset swaps credit, floating rate notes, futures and options, mortgages, repurchase agreements, and securities, as well as corporate, covered, and government bonds. Further, the company offers foreign exchange (FX) products, such as emerging markets, FX listed futures and options, FX options, ParFX, spot and forward FX, and FX exotics; market data products; and money market products, including arbitrage, cash fund management, commercial paper, deposits and certificates of deposits, forward rate agreements, bank bills, federal funds, and short dates. Additionally, it provides private equity, structured products, hedge fund secondaries, real estate secondaries, non-traditional secondaries, and GCC fixed income, as well as information services. The company was incorporated in 1959 and is based in Lausanne, Switzerland. Compagnie Financière Tradition SA is a subsidiary of Financière Vermeer NV.

Full CFNCF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this CFNCF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CFNCF vs SCHDCFNCF vs JEPICFNCF vs OCFNCF vs KOCFNCF vs MAINCFNCF vs JNJCFNCF vs MRKCFNCF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.